CONTEXT AND OBJECTIVE: Diabetic retinopathy is a disease caused by increased permeability of retinal vessels. Its incidence and prevalence have been increasing due to urbanization, greater life expectancy and the habits of modern life. Its onset is insidious and it may lead to blindness in 75% of individuals who have been diabetic for more than 20 years. The aim here was to evaluate the evidence from Cochrane systematic reviews on interventions relating to diabetic retinopathy. DESIGN AND SETTING: Review of systematic reviews, conducted at Cochrane Brazil.
INTRODUCTION
Diabetic retinopathy is a secondary retinal disease caused by vascular changes due to diabetes. It is a common complication of diabetes and is the leading cause of decreased vision in the economically active population, with large negative impacts both on public health and on the social security system. It has been estimated that, because of increased life expectancy and lifestyle changes associated with urbanization, the worldwide prevalence of diabetes will rise from 126.6 million in 2010 to 191 million in 2030. 1 According to the World Health Organization, 75% of patients with a 20-year history of type 2 diabetes have some degree of retinopathy. 2 Nonetheless, there is still no intervention capable of preventing the emergence of retinopathy or even of preventing its progression, effectively and safely. Thus, clinical practice is limited to guidance for patients in which they are advised to maintain strict glycemic control because of the risk of disease evolution.
Like other vascular changes in diabetic patients, retinopathy starts in the endothelium. This tissue modulates vascular functions through releasing or inhibiting nitric oxide, endothelin, angiotensin and other substances that act in relation to inflammation, platelet aggregation, permeability, oxidative stress, blood clotting and vascular tone. [3] [4] [5] [6] [7] Diabetic retinopathy is classified based on the degree of involvement of the retinal tissue and may be early non-proliferative, moderate non-proliferative, severe non-proliferative or proliferative. 8 Early non-proliferative retinopathy is characterized by microaneurysms seen via fundoscopy; while in moderate non-proliferative (or exudative) retinopathy, it is possible to observe hard exudates. In severe non-proliferative retinopathy, in addition to the previous changes, there are soft exudates (retinal ischemia), intraretinal abnormalities (intra-microvascular retinal anomalies, IRMA) and vessels "on rosary beads". 8 Finally, in proliferative retinopathy, there is vascular neoformation with blood extravasation, culminating in vitreous hemorrhage. At the most advanced stage, the new vessels can lead to retinal traction with subsequent retinal detachment. 9 Diabetic retinopathy is diagnosed through observation of the changes described above through direct and indirect fundoscopy, retinography, photographic records of the retina or angiofluoresceinography. 8, 9 Early diagnosis is crucial for the best response to treatments, since more advanced degrees of retinopathy have worse prognoses.
Evaluations on diabetic patients without changes seen via fundoscopy or on those with early non-proliferative diabetic retinopathy need to be made annually. Those with moderate non-proliferative diabetic retinopathy need to be evaluated every six months, and those with severe non-proliferative retinopathy, every two to four months. 10 Patients with macular edema also need to be reevaluated within six months, because if this is persistent, treatment with a macular grid is necessary in order to preserve central vision. 10 Diabetic macular edema is a complication of diabetic retinopathy. It is defined as clinically significant macular edema when it is observed in the presence of hard exudates less than 500 µm from the center of the fovea and/or retinal edema; or if the size of the macular edema is larger than the papillary diameter (1500 µm)
of the fovea, with the presence of edema, microaneurysms, soft exudates (areas of retinal ischemia) and hard exudates (lipoprotein buildups). 10, 11 The diagnosis of clinically significant macular edema is made by means of posterior pole biomicroscopy using drug-induced mydriasis.
10,11
The practical approach most used for preventing diabetic retinopathy is strict glucose control and regular eye tracking.
The therapeutic options include laser phototherapy, which includes photocoagulation and photostimulation; injection of intravitreal corticosteroids; and use of anti-vascular endothelial growth factor (VEGF) drugs (pegaptanib, ranibizumab, aflibercept and bevacizumab).
It is important to note that once macular disease has become established, treatment for diabetic retinopathy becomes essential and haste is required. On the other hand, although the therapeutic options available seem effective, they are invasive and may be associated with serious adverse events, such as visual field loss, reduced night vision, increased intraocular pressure and endophthalmitis.
Considering the global prevalence of diabetic retinopathy, its comorbidities, the consequences associated with its development and the uncertainties regarding the effectiveness and safety of the preventive and therapeutic interventions available, it is relevant to assess the current literature in order to summarize the best evidence that can guide decision-making processes relating to this important public health problem and direct future research, so as to answer questions that still remain unanswered.
OBJECTIVES
To evaluate the evidence from Cochrane systematic reviews regarding the effectiveness and safety of interventions for prevention and treatment of diabetic retinopathy.
METHODS

Design
This was a review of systematic reviews.
Setting
This review was conducted within the Postgraduate Program on
Evidence-Based Health, of the Federal University of São Paulo (Unifesp) and at Cochrane Brazil.
Criteria for including reviews
We only included the last version of completed Cochrane systematic reviews that evaluated the effects of different interventions for preventing or treating diabetic retinopathy. The protocols of systematic reviews in progress and withdrawn reviews were not considered.
Search for reviews
We carried out an electronic search in the Cochrane Library (via Wiley) on August 5, 2016, as presented in Table 1 .
Selection of reviews
Two researchers independently selected and evaluated all the systematic reviews retrieved, in order to confirm their eligibility, in accordance with the inclusion criteria.
Presentation of results
We presented all the included reviews narratively (qualitative synthesis). We considered that the key points regarding their relevance were the methods used, quality of studies included, results, quality of the body of final evidence for each outcome and applicability.
RESULTS
An initial search resulted in 21 reviews and, after reading the titles and abstracts, ten Cochrane systematic reviews (SRs) were found to be actually related to the topic and fulfilled the inclusion criteria. These were then summarized and are presented below. It is probably related to inflammatory processes. Therefore, several topical non-steroidal anti-inflammatory drugs (NSAIDs), such as 0.09% bromfenac, 0.1% nepafenac and 0.5% ketorolac have been used to treat chronic diabetics with cystoid macular edema (CMO).
The aim of these authors' review 13 was to select randomized clinical trials and "quasi" randomized trials in order to discover the effects of topical NSAIDs among diabetics with CMO. However, no study was included, since most of the studies were conducted on pseudophakic patients. Presence of pseudophakia can be considered misleading. The authors suggested that there was a need for studies on the use of NSAIDs among diabetic patients with cystoid macular edema.
They concluded that there was a need to conduct properly designed studies in order to clarify the action of this proposed intervention on the clinical condition.
Blood pressure control for diabetic retinopathy
These authors' 14 objective was to gather evidence regarding whether hypertension control had protective action relating to prevention and evolution of diabetic retinopathy, thereby preserving visual acuity, through measuring adverse events, quality of life and costs. Secondarily, they aimed to assess the behavior of different classes of antihypertensive drugs regarding the same outcomes.
Fifteen clinical trials were included in this review, with varying follow-up times, on a total of 4,157 type 1 diabetic patients and 9,512 type 2 diabetic patients, with or without hypertension. The patients were randomized into groups with intensive pressure control versus less intensive control; standard blood pressure care versus any care; and different classes of antihypertensive drugs versus placebo. Among type 1 diabetic patients, one out of five studies reported the incidence of diabetic retinopathy and one reported its progression over four to five years of treatment and follow-up; four studies assessed a composite outcome of incidence and progression along over the same period. Among the type II patients, five out of ten trials reported on the incidence and three reported on the progression of retinopathy; one out of these ten trials reported on both the incidence and the progression over the same time interval of four to five years. A test done among type II diabetic patients did not report the outcomes of interest for this review.
The evidence from these clinical trials showed that there was a benefit from treatment with intensive pressure control over a In 7 of the 15 trials, the adverse effect reported most often was death, which led to an estimated RR of 0.86 (95% CI: 0.64 to 1.14); Three trials reported hypotension as an adverse event (RR 2.08; 95% CI: 1.69 to 2.57). Ocular adverse events were described in individual trials.
In this review, the authors concluded that pressure control had a beneficial effect regarding prevention of diabetic retinopathy, but that there was no evidence that the intervention might slow down the progression of retinopathy.
Laser photocoagulation for proliferative diabetic retinopathy
Diabetic retinopathy is a complication of diabetes in which high glycemic indexes lead to damage to retinal vessels. Laser is one therapeutic option. The objective of this study 15 was to compare laser photocoagulation with no treatment or other treatments among patients with pre-proliferative diabetic retinopathy.
These authors selected randomized clinical trials on patients with this profile and allocated them into groups of photocoagulation with any type of laser other than xenon or ruby laser.
They excluded trials that compared treatments using different There was a beneficial effect on the progression of diabetic retinopathy in eyes that were treated, with a 50% reduction in the The authors concluded that laser photocoagulation remained the treatment of choice for proliferative diabetic retinopathy and suggested that studies combining photocoagulation with antiangiogenic treatment (VEGFs) should be developed.
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
Given that photocoagulation, the treatment of choice for diabetic retinopathy, has side effects of affecting the field of view and limiting night vision, the authors of this review 16 there were relatively few studies that reported these effects and the event occurred at a low rate. Thus, the power of analysis to detect any differences was low. The authors considered that the quality of the studies was suspect, with inaccuracy and inconsistency in assessing the risk of bias.
The authors concluded that the evidence from these clinical trials measuring the effectiveness and safety of anti-VEGF, for use in treating proliferative diabetic retinopathy to achieve standard benefits, was of low or very low quality. However, the results suggested that anti-VEGFs can reduce the risk of intraocular hemorrhage in people with proliferative diabetic retinopathy and that new clinical trials to elucidate these questions should be conducted carefully.
Anti-vascular endothelial growth factor for diabetic macular oedema
Diabetic macular edema is a common complication of diabetic retinopathy treated with grid or focal laser in order to prevent loss of vision. However, this treatment rarely improves vision. Thus, use of anti-VEGF has been proposed.
These authors 17 investigated the effects of preserving or improving vision, acceptance, security and quality of life with this drug. The authors concluded that there was high-quality evidence favoring use of antiangiogenic drugs, compared with photocoagulation, over a period of one to two years. They suggested that future studies should examine the real-world differences in effectiveness between the drugs used in studies monitoring patients at high cardiovascular risk.
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
In this review, 18 the authors analyzed the effects of strict glucose control versus conventional control, and evaluated whether blood glucose at below normal or at normal levels brought benefits. A search for randomized trials on type I diabetics with followups of at least one year that had been published up to 2012 was conducted. Twelve clinical trials were found, with a total of 2,230
patients with a broad-spectrum population, with follow-ups varying from one to six and a half years. Because of the nature of the intervention, these studies could not be "blinded" to hypoglycemia. Moreover, 50% of these studies were judged to present high risk of bias in at least one other category.
In the group with strict glucose control, the risk of develop- Strict control increased the risk of hypoglycemia. However, the studies were heterogeneous, and only one study, the "Diabetes
Complications Clinical Trial (DCCT)", clearly showed any increase in episodes of severe hypoglycemia. Mortality was very low in all the studies.
Pentoxifylline for diabetic retinopathy
Vascular occlusion is a leading cause of diabetic retinopathy, since chronic high glucose levels leads to changes in the vascular endothelium that culminate in arteriolar occlusion and poor retinal tissue perfusion, rather than nourishment of these ischemic areas though stimulation from vascular proliferation factors.
Pentoxifylline is a drug used in treating occlusive peripheral arterial diseases. Thus, there are clinical trials in the literature that address this subject. However, the authors of this systematic review 19 failed to include any study in their review because none of them met the inclusion criteria proposed in their protocol.
These authors concluded that photocoagulation remained the first choice for treating diabetic retinopathy. However, there was evidence that pentoxifylline would induce decreased proteinuria and albumin excretion, and would also normalize some blood patterns.
Diabetic patients treated with pentoxifylline had early absorption of retinal hemorrhage and had less neovascularization. In some cases, there was a reduction of ischemic areas. These results suggested that pentoxifylline might be effective in preventing retinal neovascularization and improving this condition. The authors suggested that further randomized clinical trials should be conducted to assess the treatment. These would be needed in order to prove the efficacy and effectiveness of pentoxifylline in relation to the evolution of diabetic retinopathy.
Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy
This Cochrane review aimed to study the effects of vitamin The authors stated that photocoagulation remained the treatment of choice for diabetic retinopathy, although there was evidence that free radicals had a role in the pathogenesis of the disease. They considered that antioxidant therapy could be helpful in preventing the progression of retinopathy, and that a combination of drugs could be needed in order to prevent visual loss among diabetic patients.
Intravitreal steroids for macular edema in diabetes
In this study, 21 
DISCUSSION
Among the ten SRs found in the Cochrane Library that discuss interventions relating to diabetic retinopathy, four present systemic strategies that might have a preventive nature, such that they might prevent progression of the disease. These strategies would have the capacity to act throughout the microcirculation.
The other six SRs analyzed local treatments for disease that had already become established.
It can be noted that among the four SRs presenting systemic interventions, "Blood pressure control for diabetic retinopathy"
and "Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus" were the ones that addressed prevention and progression of diabetic retinopathy. In the other two, "Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy" and "Pentoxifylline for diabetic retinopathy", the authors were unable to find relevant clinical trials and, in accordance with their predefined inclusion criteria, they left the topic open for future clinical trials, thereby revealing the need to study these issues.
The SR on the systemic intervention "Blood Pressure control for diabetic retinopathy" showed that there was a benefit from lowering blood pressure in relation to prevention of diabetic retinopathy that lasted for four or five years. However, it lacked evidence to show that this would slow the progression of diabetic retinopathy. This, together with the modest beneficial effect on disease incidence, weakened the conclusion that there was a benefit from intervening in blood pressure only to prevent diabetic retinopathy. In the review "Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus", there was high-quality evidence showing that strict glycemic control decreased the development of retinopathy complications, compared with standard control among young patients. However, the evidence relating to disease progression was weaker. These authors suggested that studies addressing the same outcomes among elderly patients with this disease and macrovascular complications should be conducted. Among the six SRs that investigated local therapy, three addressed anti-VEGFs: two of these reviews analyzed studies on proliferative diabetic retinopathy and one, macular edema.
One review examined clinical trials involving topical corticosteroid therapy for diabetic macular edema, and another assessed the use of non-steroidal anti-inflammatory drugs to treat cystoid macular edema. The last of these reviews examined clinical trials on photocoagulation.
In the SR "Topical non-steroidal anti-inflammatory agents for diabetic cystoid macular oedema", the authors did not include any clinical trials that might address the use of non-steroidal antiinflammatory drugs for treating cystoid macular edema. This was because all the studies eventually fell within the exclusion criteria due to the large number of confounding factors relating to the different etiologies of this pathological condition.
The SR "Laser photocoagulation for proliferative diabetic retinopathy" included five trials that did not address near vision or quality of life among the patients who received this treatment.
It found that there was little difference in visual acuity between the control group and intervention group after a twelve-month period, with low quality of evidence. There was moderate quality of evidence regarding reduction of the risk of severe loss of visual acuity. There was a benefit regarding progression of diabetic retinopathy in the intervention group, with low quality of evidence, and also a benefit regarding vitreous hemorrhage.
In the SR "Anti-vascular endothelial growth factor for proliferative diabetic retinopathy", the authors concluded that there was low or very low quality of evidence regarding the safety and efficacy of the use of anti-VEGFs in relation to proliferative diabetic retinopathy. However, they suggested that an improvement was obtained regarding vitreous hemorrhage. This went against the conclusion from the review "Anti-endothelial vascular growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy", which was a review with high-quality evidence.
Among these six SRs, many concluded that the procedure investigated was advantageous. On the other hand, they suggested that further studies should be conducted on patients presenting different profiles or at earlier stages of the disease, or using associations between the therapies to enhance their effectiveness and reduce the side effects foreseen in the procedures.
Regarding visual acuity, the use of anti-VEGF in treating proliferative retinopathy was found to improve visual acuity, with low quality of evidence. There was high-quality evidence regarding its use in macular treatment, compared with use of a macular grid.
As stated earlier, diabetic retinopathy is a disease that causes a negative impact on both health and social security through affecting the economically active population. It also affects patients' selfesteem, because of its deleterious and mutilating nature.
The treatment of choice for proliferative diabetic retinopathy continues to be peripheral retinal photocoagulation. However for treating macular disease, the use of injectable corticosteroids and anti-VEGFs is of great interest with regard to preserving and improving patients' vision. These methods are promising alternatives for treating diabetic macular edema, but further studies on the early phase of this pathological condition are required.
Regarding the implications of the present review for further research, the need for a prophylactic treatment or an option capable of at least reducing the progression of diabetic retinopathy persists even today. The aim of such treatment would be to avoid local treatments, thereby preserving the retinal tissue. Thus, the search for systemic medication that can produce effects on the entire vascular endothelium continues, with the aim of safeguarding diabetic patients' macro and microcirculation and acting as prophylaxis to avoid all the sequelae that diabetes causes to the vascular tree.
CONCLUSION
Only a few options are likely to be effective for treating diabetic retinopathy. These include photocoagulation and anti-vascular endothelial growth factor agents. Strict glucose and pressure control seem to postpone the onset of retinopathy. For macular edema, antiangiogenic drugs, intravitreal injection and surgical implantation seem to have some benefit. However, these findings came from evidence ranging from low to high quality. Lowquality evidence needs to be used with caution in clinical practice until further studies can corroborate it.
